Form 4: Rapport Therapeutics Executive Trades Shares

Rapport Therapeutics, Inc. executive Yeleswaram Krishnaswamy reports a transaction involving common stock under a pre-arranged trading plan.

Summary

• Yeleswaram Krishnaswamy, Chief Development Officer at Rapport Therapeutics, Inc., executed a transaction involving the company's common stock on April 8, 2026.
• The transaction involved the disposal of 360 shares of common stock at a price of $34.90 per share.
• Following this transaction, Krishnaswamy beneficially owns 286,516 shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as the transaction was conducted under a Rule 10b5-1 plan, mitigating concerns about insider trading, but still represents a disposal of shares by an executive.

Negatives

• An executive disposed of company stock, which could be perceived negatively by the market, although it was conducted under a Rule 10b5-1 plan.

Risks

• The disposal of shares by a key executive, even under a pre-arranged plan, could be interpreted as a lack of confidence in the company's short-term prospects by some investors.
• The specific details of the Rule 10b5-1 plan are not disclosed, which limits the ability to fully assess the context of the transaction.

Future Outlook

The filing does not contain forward-looking statements or guidance. It solely reports a past transaction.

Industry Context

StockSavvy.ai notes that Form 4 filings are routine disclosures for executives and directors, detailing changes in their beneficial ownership of company stock. Transactions executed under Rule 10b5-1 plans are designed to provide an affirmative defense against allegations of insider trading by establishing a predetermined trading schedule or strategy at a time when the executive does not possess material non-public information.

Stakeholder Impact

• Shareholders: May observe the transaction, but the Rule 10b5-1 plan context suggests it's pre-planned and not necessarily indicative of negative sentiment.
• Employees: Similar to shareholders, the impact is likely minimal due to the nature of the transaction.
• Management: The filing confirms adherence to disclosure requirements for executive stock transactions.

Key Dates

Keywords

Rapport Therapeutics, RAPP, Form 4, Insider Trading, Stock Transaction, Beneficial Ownership, Rule 10b5-1, Executive Trading, Common Stock